Back to results
US 2022/0008570 A1Published application
Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
AssigneeActinium Pharmaceuticals, Inc.
InventorDale Ludwig
Life of this patent
Estimating the term…
Abstract
Methods for treating a proliferative disease or disorder by administering a radioimmunotherapy to generate an immune response in combination with immune checkpoint therapy to further enhance the immune response.
Claims21
A method for treating a subject having a proliferative disorder, the method comprising:
- administering to the subject a therapeutically effective amount of an immune checkpoint therapy;
- and
- administering to the subject a therapeutically effective amount of a radioimmunotherapy,
- wherein the radioimmunotherapy comprises a radionuclide selected from the group comprising 131I, 125I, 123I, 90Y, 177Lu, 186Re, 188Re, 89Sr, 153Sm, 32P, 225Ac, 213Bi, 213Po, 211At, 212Bi, 213Bi, 223Ra, 227Th, 149Tb, 137Cs, 212Pb or 103Pd, or a combination thereof.
1 more element
(canceled)
A method for treating a subject having a proliferative disorder, the method comprising:
- administering to the subject a therapeutically effective amount of an immune checkpoint therapy selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, or a combination thereof;
- and
- after at least one week, administering to the subject a therapeutically effective amount of a radioimmunotherapy selected from the group consisting of CD33, CD38, CD45, DR5, HER3, or a combination thereof, wherein the radioimmunotherapy is labeled with a radionuclide selected from the group consisting of 131I, 177Lu, and 225Ac.
A method for treating a subject having a proliferative disorder, the method comprising:
- administering to the subject a therapeutically effective amount of a radioimmunotherapy selected from the group consisting of CD33, CD38, CD45, DR5, HER3, or a combination thereof, wherein the radioimmunotherapy is labeled with a radionuclide selected from the group consisting of 131I, 177Lu, and 225Ac;
- and
- after at least one week, administering to the subject a therapeutically effective amount of an immune checkpoint therapy selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, or a combination thereof.
Dependencies are inferred from the claim text.